MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR
- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia
- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility
- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023
- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021
LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress.
Posted on 553
Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.
Serving in key leadership roles on Aviceda’s Executive Leadership Team will be:
Mohamed Genead, MD, CEO & President,
David Callanan, MD, Chief Medical Officer,
Derek Kunimoto, MD, JD, Chief Operating Officer,
Michael Tolentino, MD, Chief Technology Officer, and
Christopher Scott, PhD, Chief Scientific Officer.
Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast Report 2020 Featuring Lucentis, Eylea & Ozurdex
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
This Retinal Vein Occlusion - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the RVO, historical and forecasted epidemiology as well as the RVO market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The RVO market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM RVO market size from 2017 to 2030. The report also covers current RVO treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast Report 2017-2030 - ResearchAndMarkets com galvnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from galvnews.com Daily Mail and Mail on Sunday newspapers.
Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast Report 2017-2030 - ResearchAndMarkets.com
ResearchAndMarkets.com s offering.
This Retinal Vein Occlusion - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the RVO, historical and forecasted epidemiology as well as the RVO market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The RVO market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM RVO market size from 2017 to 2030. The report also covers current RVO treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.